FDA approves KalVista’s Ekterly for hereditary angioedema
Pharmaceutical Technology
JULY 7, 2025
The positive results from the KONFIDENT trial were further supported by findings from the real-world KONFIDENT-S open-label extension study. How will RFK Jr’s American dream for vaccines play out? Ekterly has the potential to become the foundational treatment for HAE and our focus now is on delivering it to the people who need it.”
Let's personalize your content